These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
438 related articles for article (PubMed ID: 12374674)
1. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma. Atkins MB; Gollob JA; Sosman JA; McDermott DF; Tutin L; Sorokin P; Parker RA; Mier JW Clin Cancer Res; 2002 Oct; 8(10):3075-81. PubMed ID: 12374674 [TBL] [Abstract][Full Text] [Related]
2. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma. McDermott DF; Mier JW; Lawrence DP; van den Brink MR; Clancy MA; Rubin KM; Atkins MB Clin Cancer Res; 2000 Jun; 6(6):2201-8. PubMed ID: 10873069 [TBL] [Abstract][Full Text] [Related]
3. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. Legha SS; Ring S; Eton O; Bedikian A; Buzaid AC; Plager C; Papadopoulos N J Clin Oncol; 1998 May; 16(5):1752-9. PubMed ID: 9586888 [TBL] [Abstract][Full Text] [Related]
4. A phase II study of neoadjuvant biochemotherapy for stage III melanoma. Gibbs P; Anderson C; Pearlman N; LaClaire S; Becker M; Gatlin K; O'Driscoll M; Stephens J; Gonzalez R Cancer; 2002 Jan; 94(2):470-6. PubMed ID: 11900232 [TBL] [Abstract][Full Text] [Related]
5. Biochemotherapy with temozolomide, cisplatin, vinblastine, subcutaneous interleukin-2 and interferon-alpha in patients with metastatic melanoma. González Cao M; Malvehy J; Martí R; Conill C; Sánchez M; Martín M; Carrera C; Herrero J; Gascón P; Mellado B; Castel T; Puig S Melanoma Res; 2006 Feb; 16(1):59-64. PubMed ID: 16432457 [TBL] [Abstract][Full Text] [Related]
6. A biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, temozolomide (Temodal), interferon-alfa and interleukin-2 for metastatic melanoma: a phase II study. Ron IG; Sarid D; Ryvo L; Sapir EE; Schneebaum S; Metser U; Asna N; Inbar MJ; Safra T Melanoma Res; 2006 Feb; 16(1):65-9. PubMed ID: 16432458 [TBL] [Abstract][Full Text] [Related]
7. Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma. O'Day SJ; Gammon G; Boasberg PD; Martin MA; Kristedja TS; Guo M; Stern S; Edwards S; Fournier P; Weisberg M; Cannon M; Fawzy NW; Johnson TD; Essner R; Foshag LJ; Morton DL J Clin Oncol; 1999 Sep; 17(9):2752-61. PubMed ID: 10561350 [TBL] [Abstract][Full Text] [Related]
8. Phase II multicenter trial of maintenance biotherapy after induction concurrent Biochemotherapy for patients with metastatic melanoma. O'Day SJ; Atkins MB; Boasberg P; Wang HJ; Thompson JA; Anderson CM; Gonzalez R; Lutzky J; Amatruda T; Hersh EM; Weber JS J Clin Oncol; 2009 Dec; 27(36):6207-12. PubMed ID: 19917850 [TBL] [Abstract][Full Text] [Related]
9. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha. Legha SS; Ring S; Bedikian A; Plager C; Eton O; Buzaid AC; Papadopoulos N Ann Oncol; 1996 Oct; 7(8):827-35. PubMed ID: 8922197 [TBL] [Abstract][Full Text] [Related]
10. Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy. Tarhini AA; Kirkwood JM; Gooding WE; Cai C; Agarwala SS J Clin Oncol; 2007 Sep; 25(25):3802-7. PubMed ID: 17761969 [TBL] [Abstract][Full Text] [Related]
11. Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Children's Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Flaherty LE; Othus M; Atkins MB; Tuthill RJ; Thompson JA; Vetto JT; Haluska FG; Pappo AS; Sosman JA; Redman BG; Moon J; Ribas A; Kirkwood JM; Sondak VK J Clin Oncol; 2014 Nov; 32(33):3771-8. PubMed ID: 25332243 [TBL] [Abstract][Full Text] [Related]
12. A phase II study of biochemotherapy for the treatment of metastatic malignant melanoma. Gibbs P; Iannucci A; Becker M; Allen J; O'Driscoll M; McDowell K; Williams P; Rosse P; Murphy J; Gonzalez R Melanoma Res; 2000 Apr; 10(2):171-9. PubMed ID: 10803718 [TBL] [Abstract][Full Text] [Related]
13. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. Eton O; Legha SS; Bedikian AY; Lee JJ; Buzaid AC; Hodges C; Ring SE; Papadopoulos NE; Plager C; East MJ; Zhan F; Benjamin RS J Clin Oncol; 2002 Apr; 20(8):2045-52. PubMed ID: 11956264 [TBL] [Abstract][Full Text] [Related]
14. Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG). Hauschild A; Garbe C; Stolz W; Ellwanger U; Seiter S; Dummer R; Ugurel S; Sebastian G; Nashan D; Linse R; Achtelik W; Mohr P; Kaufmann R; Fey M; Ulrich J; Tilgen W Br J Cancer; 2001 Apr; 84(8):1036-42. PubMed ID: 11308250 [TBL] [Abstract][Full Text] [Related]
15. Outpatient biochemotherapy with interleukin-2 and interferon alfa-2b in patients with metastatic malignant melanoma: results of two phase II cytokine working group trials. Flaherty LE; Atkins M; Sosman J; Weiss G; Clark JI; Margolin K; Dutcher J; Gordon MS; Lotze M; Mier J; Sorokin P; Fisher RI; Appel C; Du W J Clin Oncol; 2001 Jul; 19(13):3194-202. PubMed ID: 11432886 [TBL] [Abstract][Full Text] [Related]
16. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a]. Kirchner HH; Atzpodien J; Poliwoda H Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119 [TBL] [Abstract][Full Text] [Related]
17. A retrospective study of biochemotherapy for metastatic melanoma: the importance of dose intensity. Minor DR; Madland MT; Kashani-Sabet M; Denny SR; Harvey WB Cancer Biother Radiopharm; 2005 Oct; 20(5):479-86. PubMed ID: 16248763 [TBL] [Abstract][Full Text] [Related]
18. Interleukin-2-based biochemotherapy for patients with stage IV melanoma: long-term survivors outside a clinical trial setting. Hess V; Herrmann R; Veelken H; Schwabe M Oncology; 2007; 73(1-2):33-40. PubMed ID: 18332650 [TBL] [Abstract][Full Text] [Related]
19. Biochemotherapy of metastatic melanoma in patients with or without recently diagnosed brain metastases. Majer M; Jensen RL; Shrieve DC; Watson GA; Wang M; Leachman SA; Boucher KM; Samlowski WE Cancer; 2007 Sep; 110(6):1329-37. PubMed ID: 17623835 [TBL] [Abstract][Full Text] [Related]
20. Rationale for intergroup trial E-3695 comparing concurrent biochemotherapy with cisplatin, vinblastine, and DTIC alone in patients with metastatic melanoma. Flaherty LE Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S15-20. PubMed ID: 10685653 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]